The epidemiology of gastrointestinal stromal tumor has not been well examined, and prior studies often provide conflicting results.
Dr El-Serag and colleagues from Houston, Texas conducted the first population-based study to evaluate the incidence and survival of malignant gastrointestinal stromal tumor in the United States.
The researchers utilized the Surveillance, Epidemiology, and End Results registry from the National Cancer Institute to identify all cases of malignant gastrointestinal stromal tumor diagnosed from 1992 to 2000.
The research team calculated the age-adjusted incidence rates and the survival rates and then used cox proportional hazards models to examine the risk of mortality.
The researchers reviewed a total of 1,458 cases of diagnosed gastrointestinal stromal tumor between 1992 and 2000.
| Older age, Black race, advanced stage, and receipt of therapy are independent predictors of mortality|
|The American Journal of Gastroenterology|
The research team found that the age-adjusted yearly incidence rate was 0.68/100,000 and the mean age at diagnosis was 63 yr.
54% were men and 46% were women.
The incidence rate was higher among men and among Blacks.
The researchers noted that 51% of cases were in the stomach, 36% small intestine, 7% colon, 5% rectum, and 1% in the esophagus.
53% of cases were staged as localized, 19% regional, 23% distant, and 5% unstaged.
In addition, the investigators noted that the 1- and 5-yr relative survival rates were 80% and 45%, respectively.
Cox analysis showed that older age, Black race, advanced stage, and receipt of therapy were independent predictors of mortality.
Dr El-Serag concluded, "Malignant gastrointestinal stromal tumors rare, but are more common in the older population, men, and Blacks."
"Risk factors for mortality include older age, Black race, advanced stage, and no surgical intervention."